The deal gives Incyte access to an oral Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist which, according to the companies, “has the potential to treat multiple mast cell-mediated diseases”, including atopic dermatitis, chronic inducible urticaria and chronic spontaneous urticaria.
Preclinical study results showed that the candidate, EP262, improved atopic dermatitis-like skin lesions and markers of type 2 inflammation, while an early-stage study in healthy volunteers showed it was safe and well tolerated at all tested doses.
